Key Details
Price
$10.78Annual ROE
-49.34%Beta
0.96Events Calendar
Next earnings date:
Mar 12, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Mar 12, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company's core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity.
Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024.
Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.
Bioventus Inc. (NASDAQ:BVS ) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
FAQ
- What is the primary business of Bioventus?
- What is the ticker symbol for Bioventus?
- Does Bioventus pay dividends?
- What sector is Bioventus in?
- What industry is Bioventus in?
- What country is Bioventus based in?
- When did Bioventus go public?
- Is Bioventus in the S&P 500?
- Is Bioventus in the NASDAQ 100?
- Is Bioventus in the Dow Jones?
- When was Bioventus's last earnings report?
- When does Bioventus report earnings?
- Should I buy Bioventus stock now?